Global Lupus Therapeutic Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 2,562.05 Million |
 Market Size (Forecast Year) |
USD 5,142.63 Million |
 CAGR |
% |
| Major Markets Players |
Global Lupus Therapeutic Market, By Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus), Treatment (Corticosteroids, Immunosuppressive Drugs, Biologic Drugs, Antihypertensive Drugs, Others), Diagnosis (Laboratory Tests, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the lupus therapeutic market is anticipated to grow rapidly during the forecast period. The Lupus Foundation of America estimates that 1.5 million Americans have lupus, with 16,000 new cases recorded each year in the Americas. Lupus is a chronic autoimmune illness in which the immune system of the body fails to identify its own cells and tissues and attacks them. Your immune system attacks your skin in cutaneous (skin) lupus. Skin lupus affects about 10% of all lupus cases, while skin lupus affects 65 percent of patients with systemic lupus.
Data Bridge Market Research analyses that the lupus therapeutic market was valued at USD 2,562.05 million in 2021 and is expected to reach USD 5,142.63 million by 2029, registering a CAGR of 9.10% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Lupus is an autoimmune inflammatory condition in which the body's immune system becomes overactive and begins attacking healthy tissues. Swelling, inflammation, skin rashes, and joint discomfort are all common signs and symptoms of lupus. Lupus therapies are a type of therapeutic that is often used to treat lupus illnesses.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus), Treatment (Corticosteroids, Immunosuppressive Drugs, Biologic Drugs, Antihypertensive Drugs, Others), Diagnosis (Laboratory Tests, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
LEO Pharma A/S (Denmark), Zydus Cadila (India), Amneal Pharmaceuticals LLC. (US), Glenmark Pharmaceuticals Limited (India), Hikma Pharmaceuticals PLC (UK), Dr. Reddy’s Laboratories Ltd. (India), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Bausch Health Companies Inc. (Canada), Eli Lilly and Company (US), AbbVie Inc. (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Pfizer Inc. (US), GlaxoSmithKline plc (UK) |
|
Market Opportunities |
|
Lupus Therapeutic Market Dynamics
Drivers
- Increasing prevalence of lupus
The rising prevalence of lupus is anticipated to influence the lupus therapeutic market's growth. Lupus is an autoimmune disease in which the immune system of the body becomes overactive and targets normal, healthy tissue. Inflammation, swelling, and damage to the joints, skin, kidneys, blood, heart, and lungs are some of the symptoms.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of lupus therapeutic market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the lupus therapeutic market. Additionally, high disposable income and increase in the demand for effective therapies will result in the expansion of lupus therapeutic market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the lupus therapeutic market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the lupus therapeutic market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of lupus will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the lupus therapeutic market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This lupus therapeutic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lupus therapeutic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Lupus is far more common in women. Women between the ages of 15 and 44 make up over 90% of those diagnosed with lupus. It is, however, available to persons of all genders and ages. Lupus commonly appears in children at the age of 12.
Lupus therapeutic market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Lupus Therapeutic Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of lupus therapeutic in recent months.
Recent Development
- In August 2021, AstraZeneca had announced the approval of Food and Drug Administration (FDA) for Saphnelo (anifrolumab) in the US. Saphnelo is a first-in-class type I interferon receptor antibody that is the first novel treatment for patients with systemic lupus erythematosus in more than a decade.
Global Lupus Therapeutic Market Scope
The lupus therapeutic market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus,
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
Treatment
- Corticosteroids
- Immunosuppressive Drugs
- Biologic Drugs
- Antihypertensive Drugs
- Others
Diagnosis
- Laboratory Tests
- Antinuclear antibody (ANA) test
- Urinalysis
- Kidney and liver assessment
- Erythrocyte sedimentation rate
- Complete blood count
- Biopsy
- Imaging Tests
- Echocardiogram
- Chest X-ray
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Lupus Therapeutic Market Regional Analysis/Insights
The Lupus therapeutic market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Lupus therapeutic market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the lupus therapeutic market because of the growing prevalence of lupus in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Lupus Therapeutic Market Share Analysis
The Lupus therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lupus therapeutic market.
Some of the major players operating in the lupus therapeutic market are:
- LEO Pharma A/S (Denmark)
- Zydus Cadila (India)
- Amneal Pharmaceuticals LLC. (US)
- Glenmark Pharmaceuticals Limited (India)
- Hikma Pharmaceuticals PLC (UK)
- Dr. Reddy’s Laboratories Ltd. (India)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Bausch Health Companies Inc. (Canada)
- Eli Lilly and Company (US)
- AbbVie Inc. (US)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Allergan (Ireland)
- Merck & Co., Inc. (US)
- Sumitomo Corporation (Japan)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
